Kuittinen T, Rovio P, Luukkaala T, Laurila M, Grénman S, Kallioniemi A et al. Paclitaxel, carboplatin and 1,25-D3 inhibit proliferation of ovarian cancer cells in vitro. Anticancer Research. 2020 kesä 1;40(6):3129-3138. https://doi.org/10.2196/10.21873/anticanres.14294

Kohvakka A, Sattari M, Shcherban A, Annala M, Urbanucci A, Kesseli J et al. AR and ERG drive the expression of prostate cancer specific long noncoding RNAs. Oncogene. 2020;39:5241–5251. https://doi.org/10.1038/s41388-020-1365-6

Lehti M, Valkeinen H, Sipilä S, Perhonen M, Rottensteiner M, Pullinen T et al. Effects of aerobic and strength training on aerobic capacity, muscle strength, and gene expression of lymphomonocytes in patients with stable CAD. American Journal of Translational Research. 2020;12(8):4582-4593.

Nissinen SI, Roine A, Hokkinen L, Karjalainen M, Venäläinen M, Helminen H et al. Detection of Pancreatic Cancer by Urine Volatile Organic Compound Analysis. Anticancer Research. 2019 tammi;39(1):73-79. https://doi.org/10.21873/anticanres.13081

Nurmi A, Muranen TA, Pelttari LM, Kiiski JI, Heikkinen T, Lehto S et al. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients. International Journal of Cancer. 2019. https://doi.org/10.1002/ijc.32309

Venäläinen MK, Roine AN, Häkkinen MR, Vepsäläinen JJ, Kumpulainen PS, Kiviniemi MS et al. Altered polyamine profiles in colorectal cancer. Anticancer Research. 2018 kesä 1;38(6):3601-3607. https://doi.org/10.21873/anticanres.12634

Vuorinen EM, Rajala NK, Ihalainen TO, Kallioniemi A. Depletion of nuclear import protein karyopherin alpha 7 (KPNA7) induces mitotic defects and deformation of nuclei in cancer cells. BMC Cancer. 2018 maalis 27;18(1). 325. https://doi.org/10.1186/s12885-018-4261-5

Granberg KJ, Annala M, Lehtinen B, Kesseli J, Haapasalo J, Ruusuvuori P et al. Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas. Neuro-Oncology. 2017 syys 1;19(9):1206-1216. https://doi.org/10.1093/neuonc/nox028

Lehtinen B, Raita A, Kesseli J, Annala M, Nordfors K, Yli-Harja O et al. Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas. BMC Cancer. 2017 touko 3;17(1). 310. https://doi.org/10.1186/s12885-017-3274-9

Wu X, Bhattarai A, Korkola P, Pertovaara H, Eskola H, Kellokumpu-Lehtinen PL. The Association Between Liver and Tumor [18F]FDG Uptake in Patients with Diffuse Large B Cell Lymphoma During Chemotherapy. Molecular Imaging and Biology. 2017;19(5):787–794. https://doi.org/10.1007/s11307-017-1044-3

Kuusela J, Kim J, Räsänen E, Aalto-Setälä K. The Effects of Pharmacological Compounds on Beat Rate Variations in Human Long QT-Syndrome Cardiomyocytes. Stem Cell Reviews and Reports. 2016;12(6):698–707. https://doi.org/10.1007/s12015-016-9686-0

Manzini S, Viiri LE, Marttila S, Aalto-Setälä K. A Comparative View on Easy to Deploy non-Integrating Methods for Patient-Specific iPSC Production. Stem Cell Reviews and Reports. 2015 joulu 1;11(6):900-908. https://doi.org/10.1007/s12015-015-9619-3

Friis S, Kesminiene A, Espina C, Auvinen A, Straif K, Schüz J. European Code against Cancer 4th Edition: Medical exposures, including hormone therapy, and cancer. CANCER EPIDEMIOLOGY. 2015 joulu 1;39:S107-S119. https://doi.org/10.1016/j.canep.2015.08.003

McColl N, Auvinen A, Kesminiene A, Espina C, Erdmann F, de Vries E et al. European Code against Cancer 4th Edition: Ionising and non-ionising radiation and cancer. CANCER EPIDEMIOLOGY. 2015 joulu 1;39:S93-S100. https://doi.org/10.1016/j.canep.2015.03.016

Greinert R, de Vries E, Erdmann F, Espina C, Auvinen A, Kesminiene A et al. European Code against Cancer 4th Edition: Ultraviolet radiation and cancer. CANCER EPIDEMIOLOGY. 2015 joulu 1;39:S75-S83. https://doi.org/10.1016/j.canep.2014.12.014

Hietanen T, Pitkänen M, Kapanen M, Kellokumpu-Lehtinen PL. Effects of single and fractionated irradiation on natural killer cell populations: Radiobiological characteristics of viability and cytotoxicity in vitro. Anticancer Research. 2015 loka 1;35(10):5193-5200.

Ylipää A, Kivinummi K, Kohvakka A, Annala M, Latonen L, Scaravilli M et al. Transcriptome sequencing reveals PCAT5 as a Novel ERG-Regulated long Noncoding RNA in prostate cancer. Cancer Research. 2015 loka 1;75(19):4026-4031. https://doi.org/10.1158/0008-5472.CAN-15-0217

Pashayan N, Pharoah PDP, Schleutker J, Talala K, Tammela TLJ, Määttänen L et al. Reducing overdiagnosis by polygenic risk-stratified screening: Findings from the Finnish section of the ERSPC. British Journal of Cancer. 2015 syys 29;113(7):1086-1093. https://doi.org/10.1038/bjc.2015.289

Umbehr MH, Gurel B, Murtola TJ, Sutcliffe S, Peskoe SB, Tangen CM et al. Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ngml-1, normal DRE and negative for prostate cancer. PROSTATE CANCER AND PROSTATIC DISEASES. 2015 syys 14;18(3):264-269. https://doi.org/10.1038/pcan.2015.19

Kaapu KJ, Ahti J, Tammela TLJ, Auvinen A, Murtola TJ. Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population-based case-control study. International Journal of Cancer. 2015 syys 1;137(5):1187-1195. https://doi.org/10.1002/ijc.29470

Rane JK, Ylipää A, Adamson R, Mann VM, Simms MS, Collins AT et al. Construction of therapeutically relevant human prostate epithelial fate map by utilising miRNA and mRNA microarray expression data. British Journal of Cancer. 2015 elo 11;113(4):611-615. https://doi.org/10.1038/bjc.2015.262

Sousa S, Brion R, Lintunen M, Kronqvist P, Sandholm J, Mönkkönen J et al. Human breast cancer cells educate macrophages toward the M2 activation status. BREAST CANCER RESEARCH. 2015 elo 5;17(1). 101. https://doi.org/10.1186/s13058-015-0621-0

Kapanen M, Laaksomaa M, Tulijoki T, Kellokumpu-Lehtinen PL, Hyödynmaa S. Effects of remedies made in patient setup process on residual setup errors and margins in head and neck cancer radiotherapy based on 2D image guidance. Reports of Practical Oncology and Radiotherapy. 2015 heinä 1;20(4):292-298. https://doi.org/10.1016/j.rpor.2015.03.002

Zoni E, Van Der Horst G, Van De Merbel AF, Chen L, Rane JK, Pelger RCM et al. MIR-25 modulates invasivenessand dissemination of human prostate cancer cells via regulation of αv-and α6-integrin expression. Cancer Research. 2015 kesä 1;75(11):2326-2336. https://doi.org/10.1158/0008-5472.CAN-14-2155

Thomsen FB, Brasso K, Christensen IJ, Johansson JE, Angelsen A, Tammela TLJ et al. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study. EUROPEAN JOURNAL OF CANCER. 2015 touko 30;51(10):1283-1292. https://doi.org/10.1016/j.ejca.2015.03.021

Laitinen VH, Rantapero T, Fischer D, Vuorinen EM, Tammela TLJ, Wahlfors T et al. Fine-mapping the 2q37 and 17q11.2-q22 loci for novel genes and sequence variants associated with a genetic predisposition to prostate cancer. International Journal of Cancer. 2015 touko 15;136(10):2316-2327. https://doi.org/10.1002/ijc.29276

Kilpeläinen TP, Tammela TLJ, Malila N, Hakama M, Santti H, Määttänen L et al. The Finnish prostate cancer screening trial: Analyses on the screening failures. International Journal of Cancer. 2015 touko 15;136(10):2437-2443. https://doi.org/10.1002/ijc.29300

Saarimäki L, Tammela TL, Määttänen L, Taari K, Kujala PM, Raitanen J et al. Family history in the finnish prostate cancer screening trial. International Journal of Cancer. 2015 touko 1;136(9):2172-2177. https://doi.org/10.1002/ijc.29243

Veskimäe K, Staff S, Tabaro F, Nykter M, Isola J, Mäenpää J. Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies. Genes Chromosomes and Cancer. 2015 touko 1;54(5):276-287. https://doi.org/10.1002/gcc.22241

Saurus P, Kuusela S, Lehtonen E, Hyvönen ME, Ristola M, Fogarty CL et al. Podocyte apoptosis is prevented by blocking the Toll-like receptor pathway. CELL DEATH AND DISEASE. 2015 touko 1;6(5). e1752. https://doi.org/10.1038/cddis.2015.125

Schüz J, Espina C, Villain P, Herrero R, Leon ME, Minozzi S et al. European code against cancer 4th edition: 12 ways to reduce your cancer risk. CANCER EPIDEMIOLOGY. 2015 huhti 9;39:S1-S10. https://doi.org/10.1016/j.canep.2015.05.009

Tuohinen SS, Skyttä T, Virtanen V, Luukkaala T, Kellokumpu-Lehtinen PL, Raatikainen P. Early effects of adjuvant breast cancer radiotherapy on right ventricular systolic and diastolic function. Anticancer Research. 2015 huhti 1;35(4):2141-2147.

Skyttä T, Tuohinen S, Virtanen V, Raatikainen P, Kellokumpu-Lehtinen PL. The concurrent use of aromatase inhibitors and radiotherapy induces echocardiographic changes in patients with breast cancer. Anticancer Research. 2015 maalis 1;35(3):1559-1566.

Virman JP, Bono P, Luukkaala T, Sunela K, Kujala P, Kellokumpu-Lehtinen PL. VEGFR3 and CD31 as prognostic factors in renal cell cancer. Anticancer Research. 2015 helmi 1;35(2):921-927.

Emmert-Streib F, Zhang SD, Hamilton P. Computational cancer biology: education is a natural key to many locks. BMC Cancer. 2015 tammi 15;15(1). 7. https://doi.org/10.1186/s12885-014-1002-2

Heijnsdijk EAM, De Carvalho TMD, Auvinen A, Zappa M, Nelen V, Kwiatkowski M et al. Cost-effectiveness of prostate cancer screening: A simulation study based on ERSPC data. JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2015 tammi 1;107(1). dju366. https://doi.org/10.1093/jnci/dju366

Azaïs H, Moussaron A, Bach SK, Bassil A, Betrouni N, Frochot C et al. FRα: une cible pour la thérapie photodynamique prophylactique des métastases péritonéales ovariennes? BULLETIN DU CANCER. 2014 joulu 1;101(12):1109-1113. https://doi.org/10.1684/bdc.2014.1977

Laaksomaa M, Kapanen M, Skyttä T, Peltola S, Hyödynmaa S, Kellokumpu-Lehtinen PL. Estimation of optimal matching position for orthogonal kV setup images and minimal setup margins in radiotherapy of whole breast and lymph node areas. Reports of Practical Oncology and Radiotherapy. 2014 marras 1;19(6):369-375. https://doi.org/10.1016/j.rpor.2014.05.001

Virman JP, Soini Y, Kujala P, Luukkaala T, Salminen T, Sunela K et al. Claudins as prognostic factors for renal cell cancer. Anticancer Research. 2014 elo 1;34(8):4181-4188.

Carlsson S, Roobol MJ, Schröder FH, Hugosson J, Auvinen A. RE: Prostate-specific antigen screening trials and prostate cancer deaths: The androgen deprivation connection. JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2014 touko 14;106(5). dju079. https://doi.org/10.1093/jnci/dju079

Auvinen A, Seppä K, Pasanen K, Kurttio P, Patama T, Pukkala E et al. Chernobyl fallout and cancer incidence in Finland 1988-2007. International Journal of Cancer. 2014 touko 1;134(9):2253-2263. https://doi.org/10.1002/ijc.28554

Mäenpa J, Puistola U, Riska H, Sintonen H, Saarni O, Juvonen E et al. Impact of epoetin-beta on anemia and health-related quality of life in cancer patients: A prospective observational study using the generic 15D instrument. Anticancer Research. 2014 touko 1;34(5):2325-2330.

Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen MM, Thorsen K et al. Hypermethylation of the GABRẼmiR-452̃miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy. Clinical Cancer Research. 2014 huhti 15;20(8):2169-2181. https://doi.org/10.1158/1078-0432.CCR-13-2642

Penttinen H, Rautalin M, Roine R, Jahkola T, Kellokumpu-Lehtinen PL, Huovinen R et al. Quality of life of recently treated patients with breast cancer. Anticancer Research. 2014 maalis 1;34(3):1201-1206.

Schrecengost RS, Dean JL, Goodwin JF, Schiewer MJ, Urban MW, Stanek TJ et al. USP22 regulates oncogenic signaling pathways to drive lethal cancer progression. Cancer Research. 2014 tammi 1;74(1):272-286. https://doi.org/10.1158/0008-5472.CAN-13-1954

Traylor M, Mäkelä KM, Kilarski LL, Holliday EG, Devan WJ, Nalls MA et al. A Novel MMP12 Locus Is Associated with Large Artery Atherosclerotic Stroke Using a Genome-Wide Age-at-Onset Informed Approach. PLOS GENETICS. 2014;10(7). e1004469. https://doi.org/10.1371/journal.pgen.1004469

Fitzpatrick JM, Bellmunt J, Fizazi K, Heidenreich A, Sternberg CN, Tombal B et al. Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. EUROPEAN JOURNAL OF CANCER. 2014;50(9):1617-1627. https://doi.org/10.1016/j.ejca.2014.03.010

Veitonmäki T, Murtola TJ, Määttänen L, Taari K, Stenman UH, Tammela TL et al. Prostate cancer risk and nonsteroidal antiinflammatory drug use in the Finnish prostate cancer screening trial. British Journal of Cancer. 2014;111(7):1421-1431. https://doi.org/10.1038/bjc.2014.381

Laurila EM, Kallioniemi A. The diverse role of miR-31 in regulating cancer associated phenotypes. Genes Chromosomes and Cancer. 2013 joulu;52(12):1103-1113. https://doi.org/10.1002/gcc.22107

Khanna A, Kauko O, Böckelman C, Laine A, Schreck I, Partanen JI et al. Chk1 targeting reactivates PP2A tumor suppressor activity in cancer cells. Cancer Research. 2013 marras 15;73(22):6757-6769. https://doi.org/10.1158/0008-5472.CAN-13-1002

Kellokumpu-Lehtinen PL, Tuunanen T, Kautio AL, Lehtinen I, Tanner M. Bi-weekly paclitaxel and capecitabine as a second- Or third-line treatment for advanced breast cancer: A pilot study. Anticancer Research. 2013 marras;33(11):4941-4945.

Kurttio P, Seppä K, Pasanen K, Patama T, Auvinen A, Pukkala E et al. Fallout from the Chernobyl accident and overall cancer incidence in Finland. CANCER EPIDEMIOLOGY. 2013 loka;37(5):585-592. https://doi.org/10.1016/j.canep.2013.05.006

Nurminen R, Lehtonen R, Auvinen A, Tammela TLJ, Wahlfors T, Schleutker J. Fine mapping of 11q13.5 identifies regions associated with prostate cancer and prostate cancer death. EUROPEAN JOURNAL OF CANCER. 2013 loka;49(15):3335-3343. https://doi.org/10.1016/j.ejca.2013.06.006

Ampuja M, Jokimäki R, Juuti-Uusitalo K, Rodriguez-Martinez A, Alarmo EL, Kallioniemi A. BMP4 inhibits the proliferation of breast cancer cells and induces an MMP-dependent migratory phenotype in MDA-MB-231 cells in 3D environment. BMC Cancer. 2013 syys 22;13. 429. https://doi.org/10.1186/1471-2407-13-429

Högnäs G, Hämälistö S, Rilla K, Laine JO, Vilkki V, Murumägi A et al. Aneuploidy facilitates oncogenic transformation via specific genetic alterations, including Twist2 upregulation. Carcinogenesis. 2013 syys;34(9):2000-2009. https://doi.org/10.1093/carcin/bgt171

Rahu K, Hakulinen T, Smailyte G, Stengrevics A, Auvinen A, Inskip PD et al. Site-specific cancer risk in the Baltic cohort of Chernobyl cleanup workers, 1986-2007. EUROPEAN JOURNAL OF CANCER. 2013 syys;49(13):2926-2933. https://doi.org/10.1016/j.ejca.2013.04.014

Dixit D, Ghildiyal R, Anto NP, Ghosh S, Sharma V, Sen E. Guggulsterone sensitizes glioblastoma cells to Sonic hedgehog inhibitor SANT-1 induced apoptosis in a Ras/NFκB dependent manner. Cancer Letters. 2013 elo 19;336(2):347-358. https://doi.org/10.1016/j.canlet.2013.03.025

Loi S, Michiels S, Lambrechts D, Fumagalli D, Claes B, Kellokumpu-Lehtinen PL et al. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2013 heinä 3;105(13):960-967. https://doi.org/10.1093/jnci/djt121

Liu W, Xie CC, Thomas CY, Kim ST, Lindberg J, Egevad L et al. Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer. 2013 heinä 1;119(13):2405-2412. https://doi.org/10.1002/cncr.27954

Kellokumpu-Lehtinen P, Tuunanen T, Asola R, Elomaa L, Heikkinen M, Kokko R et al. Weekly paclitaxel-An effective treatment for advanced breast cancer. Anticancer Research. 2013 kesä;33(6):2623-2628.

Kilpeläinen TP, Tammela TL, Malila N, Hakama M, Santti H, Määttänen L et al. Prostate cancer mortality in the finnish randomized screening trial. JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2013 touko 15;105(10):719-725. https://doi.org/10.1093/jnci/djt038

Elme A, Utriainen M, Kellokumpu-Lehtinen P, Palva T, Luoto R, Nikander R et al. Obesity and physical inactivity are related to impaired physical health of breast cancer survivors. Anticancer Research. 2013 huhti;33(4):1595-1602.

Bruchmann A, Roller C, Walther TV, Schäfer G, Lehmusvaara S, Visakorpi T et al. Bcl-2 associated athanogene 5 (Bag5) is overexpressed in prostate cancer and inhibits ER-stress induced apoptosis. BMC Cancer. 2013 maalis 1;13. 96. https://doi.org/10.1186/1471-2407-13-96

Veitonmäki T, Tammela TLJ, Auvinen A, Murtola TJ. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. EUROPEAN JOURNAL OF CANCER. 2013 maalis;49(4):938-945. https://doi.org/10.1016/j.ejca.2012.09.030

Rauhala HE, Teppo S, Niemelä S, Kallioniemi A. Silencing of the arp2/3 complex disturbs pancreatic cancer cell migration. Anticancer Research. 2013 tammi;33(1):45-52.

Rantanen T, Kauttu T, Åkerla J, Honkanen T, Krogerus L, Salo J et al. CIP2A expression and prognostic role in patients with esophageal adenocarcinoma. MEDICAL ONCOLOGY. 2013;30(3). 684. https://doi.org/10.1007/s12032-013-0684-7

Jayakrishnan R, Mathew A, Uutela A, Auvinen A, Sebastian P. Multiple approaches and participation rate for a community based smoking cessation intervention trial in rural Kerala, India. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION. 2013;14(5):2891-2896. https://doi.org/10.7314/APJCP.2013.14.5.2891

Jayakrishnan R, Uutela A, Mathew A, Auvinen A, Mathew PS, Sebastian P. Smoking cessation intervention in Rural Kerala, India: Findings of a randomised controlled trial. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION. 2013;14(11):6797-6802. https://doi.org/10.7314/APJCP.2013.14.11.6797

Pukkala E, Helminen M, Haldorsen T, Hammar N, Kojo K, Linnersjö A et al. Cancer incidence among Nordic airline cabin crew. International Journal of Cancer. 2012 joulu 15;131(12):2886-2897. https://doi.org/10.1002/ijc.27551

Wu GHM, Auvinen A, Määttänen L, Tammela TLJ, Stenman UH, Hakama M et al. Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening. International Journal of Cancer. 2012 syys 15;131(6):1367-1375. https://doi.org/10.1002/ijc.27340

Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TLJ, Ke C et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 syys 10;30(26):3271-3276. https://doi.org/10.1200/JCO.2011.38.8850

Saarto T, Penttinen HM, Sievänen H, Kellokumpu-Lehtinen PL, Hakamies-Blomqvist L, Nikander R et al. Effectiveness of a 12-month exercise program on physical performance and quality of life of breast cancer survivors. Anticancer Research. 2012 syys;32(9):3875-3884.

Egerdie RB, Saad F, Smith MR, Tammela TLJ, Heracek J, Sieber P et al. Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. PROSTATE CANCER AND PROSTATIC DISEASES. 2012 syys;15(3):308-312. https://doi.org/10.1038/pcan.2012.18

Kellokumpu-Lehtinen PL, Hjälm-Eriksson M, Thellenberg-Karlsson C, Åström L, Franzen L, Marttila T et al. Toxicity in patients receiving adjuvant docetaxel hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: A preplanned safety report of the SPCG-13 trial. PROSTATE CANCER AND PROSTATIC DISEASES. 2012 syys;15(3):303-307. https://doi.org/10.1038/pcan.2012.13

Liu W, Lindberg J, Sui G, Luo J, Egevad L, Li T et al. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene. 2012 elo 30;31(35):3939-3948. https://doi.org/10.1038/onc.2011.554

Högnäs G, Tuomi S, Veltel S, Mattila E, Murumägi A, Edgren H et al. Cytokinesis failure due to derailed integrin traffic induces aneuploidy and oncogenic transformation in vitro and in vivo. Oncogene. 2012 elo 2;31(31):3597-3606. https://doi.org/10.1038/onc.2011.527

Hervonen P, Tulijoki T, Kellokumpu-Lehtinen P. No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer. Anticancer Research. 2012 elo;32(8):3305-3310.

Inouye M, Ripatti S, Kettunen J, Lyytikäinen LP, Oksala N, Laurila PP et al. Novel Loci for Metabolic Networks and Multi-Tissue Expression Studies Reveal Genes for Atherosclerosis. PLOS GENETICS. 2012 elo;8(8). e1002907. https://doi.org/10.1371/journal.pgen.1002907

Martens-Uzunova ES, Jalava SE, Dits NF, Van Leenders GJLH, Møller S, Trapman J et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene. 2012 helmi 23;31(8):978-991. https://doi.org/10.1038/onc.2011.304

Bryant RJ, Pawlowski T, Catto JWF, Marsden G, Vessella RL, Rhees B et al. Changes in circulating microRNA levels associated with prostate cancer. British Journal of Cancer. 2012 helmi 14;106(4):768-774. https://doi.org/10.1038/bjc.2011.595

Dixit D, Sharma V, Ghosh S, Mehta VS, Sen E. Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition. CELL DEATH AND DISEASE. 2012 helmi;3(2). e271. https://doi.org/10.1038/cddis.2012.10

Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R et al. Adjuvant capecitabine, docetaxel, cyclophosphamide,and epirubicin for early breast cancer: Final analysis of the randomized FinXX trial. JOURNAL OF CLINICAL ONCOLOGY. 2012 tammi 1;30(1):11-18. https://doi.org/10.1200/JCO.2011.35.4639

Kilpeläinen TP, Tammela TLJ, Roobol M, Hugosson J, Ciatto S, Nelen V et al. False-positive screening results in the European randomized study of screening for prostate cancer. EUROPEAN JOURNAL OF CANCER. 2011 joulu;47(18):2698-2705. https://doi.org/10.1016/j.ejca.2011.06.055

Koskinen MJ, Kautio AL, Haanpää ML, Haapasalo HK, Kellokumpu-Lehtinen PL, Saarto T et al. Intraepidermal nerve fibre density in cancer patients receiving adjuvant chemotherapy. Anticancer Research. 2011 joulu;31(12):4413-4416.

Haillot O, Fraga A, MacIukiewicz P, Pushkar D, Tammela T, Höfner K et al. The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study. PROSTATE CANCER AND PROSTATIC DISEASES. 2011 joulu;14(4):302-306. https://doi.org/10.1038/pcan.2011.13

Cropp CD, Simpson CL, Wahlfors T, Ha N, George A, Jones MS et al. Genome-wide linkage scan for prostate cancer susceptibility in Finland: Evidence for a novel locus on 2q37.3 and confirmation of signal on 17q21-q22. International Journal of Cancer. 2011 marras 15;129(10):2400-2407. https://doi.org/10.1002/ijc.25906

Vihinen PP, Ramadan S, Vuoristo MS, Hernberg M, Tyynelä-Korhonen K, Skyttä T et al. Circulating levels of VEGFR-1 and VEGFR-2 in patients with metastatic melanoma treated with chemoimmunotherapy alone or combined with bevacizumab. MELANOMA RESEARCH. 2011 loka;21(5):431-437. https://doi.org/10.1097/CMR.0b013e32834941d3

Kemppainen KJ, Tammela TLJ, Auvinen A, Murtola TJ. The association between antihypertensive drug use and incidence of prostate cancer in Finland: A population-based case-control study. Cancer Causes and Control. 2011 loka;22(10):1445-1452. https://doi.org/10.1007/s10552-011-9819-3

Larjavaara S, Feychting M, Sankila R, Johansen C, Klaeboe L, Schüz J et al. Incidence trends of vestibular schwannomas in Denmark, Finland, Norway and Sweden in 1987-2007. British Journal of Cancer. 2011 syys 27;105(7):1069-1075. https://doi.org/10.1038/bjc.2011.344

Mattila H, Schindler M, Isotalo J, Ikonen T, Vihinen M, Oja H et al. NMD and microRNA expression profiling of the HPCX1 locus reveal MAGEC1 as a candidate prostate cancer predisposition gene. BMC Cancer. 2011 elo 2;11. 327. https://doi.org/10.1186/1471-2407-11-327

Nurminen R, Wahlfors T, Tammela TLJ, Schleutker J. Identification of an aggressive prostate cancer predisposing variant at 11q13. International Journal of Cancer. 2011 elo 1;129(3):599-606. https://doi.org/10.1002/ijc.25754

Colin P, Estevez JP, Betrouni N, Nevoux P, Puech P, Leroy X et al. Thérapie photodynamique et carcinomes urothéliaux. BULLETIN DU CANCER. 2011 heinä;98(7):769-778. https://doi.org/10.1684/bdc.2011.1389

Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM. Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression. Cancer Research. 2011 maalis 15;71(6):2108-2117. https://doi.org/10.1158/0008-5472.CAN-10-1998

Latonen L, Moore HM, Bai B, Jäämaa S, Laiho M. Proteasome inhibitors induce nucleolar aggregation of proteasome target proteins and polyadenylated RNA by altering ubiquitin availability. Oncogene. 2011 helmi 17;30(7):790-805. https://doi.org/10.1038/onc.2010.469

Schüz J, Elliott P, Auvinen A, Kromhout H, Poulsen AH, Johansen C et al. An international prospective cohort study of mobile phone users and health (Cosmos): Design considerations and enrolment. CANCER EPIDEMIOLOGY. 2011 helmi;35(1):37-43. https://doi.org/10.1016/j.canep.2010.08.001

Schwartzman J, Mongoue-Tchokote S, Gibbs A, Gao L, Corless CL, Jin J et al. A DNA methylation microarray-based study identifies ERG as a gene commonly methylated in prostate cancer. EPIGENETICS. 2011;6(10):1248-1256. https://doi.org/10.4161/epi.6.10.17727